A practical reference on visceral fat: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-11. Anything still debated is marked as such rather than presented as settled.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
adenylyl sulfate + 2 glutathione The 3 substrates of this enzyme are adenosine monophosphate, sulfite, and glutathione disulfide, whereas its two products are adenylyl sulfate and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is AMP,sulfite:glutathione-disulfide oxidoreductase (adenosine-5'-phosphosulfate-forming). Other names in common use include 5'-adenylylsulfate reductase (also used for, internal_xref(ec_num(1,8,99,2))), AMP,sulfite:oxidized-glutathione oxidoreductase, (adenosine-5'-phosphosulfate-forming), and plant-type 5'-adenylylsulfate reductase. In plants, APS is reduced by the plastidic enzyme APS reductase (APR; EC 1.8.4.9) in the presence of physiological concentrations of reduced glutathione (GSH), which acts as an electron donor.
==== MeSH E05.300.530 – injections ==== MeSH E05.300.530.370 – injections, intra-arterial MeSH E05.300.530.380 – injections, intra-articular MeSH E05.300.530.430 – injections, intralesional MeSH E05.300.530.440 – injections, intralymphatic MeSH E05.300.530.460 – injections, intramuscular MeSH E05.300.530.490 – injections, intraperitoneal MeSH E05.300.530.540 – injections, intravenous MeSH E05.300.530.550 – injections, intraventricular MeSH E05.300.530.580 – injections, spinal MeSH E05.300.530.580.300 – injections, epidural MeSH E05.300.530.580.300.145 – blood patch, epidural MeSH E05.300.530.620 – injections, subcutaneous MeSH E05.300.530.620.410 – injections, intradermal MeSH E05.300.530.620.570 – injections, jet MeSH E05.300.530.620.570.100 – biolistics MeSH E05.300.530.690 – microinjections
Heterolytic fragmentation is bond cleavage where the bonding electrons remain with only one of the fragment species. In CID, charge remote fragmentation is a type of covalent bond breaking that occurs in a gas phase ion in which the cleaved bond is not adjacent to the location of the charge. This fragmentation can be observed using tandem mass spectrometry.
=== Formulations === Metoprolol was synthesized and its activity discovered in 1969. The specific agent in on-market formulations of metoprolol is either metoprolol tartrate or metoprolol succinate, where tartrate is an immediate-release formulation and the succinate is an extended-release formulation (with 100 mg metoprolol tartrate corresponding to 95 mg metoprolol succinate). Metoprolol tartrate was first developed by Novartis and this dosage form received approval in the US in 1978. The extended-release salt, metoprolol succinate was developed by Astra Pharmaceuticals, and received a US patent in 1992.
21 February – The Government agreed a more targeted cost-of-living package, along with some universal payments, with €470m to be allocated for social protection measures. 22 February – Róisín Shortall and Catherine Murphy announced that they would stand down as co-leaders of the Social Democrats, with a successor to be appointed "at an early date." On 26 February, Holly Cairns was announced as the next leader of the party. 28 February – Minister for Education Norma Foley reversed a plan for Leaving Certificate candidates to sit Paper 1 of their English and Irish exams at the end of fifth year, after facing strong opposition from a number of organisations, including teacher and student representative bodies.
Sources: en.wikipedia.org
1888: American chemist Josephine Silone Yates was appointed head of the Department of Natural Sciences at Lincoln Institute (later Lincoln University), becoming the first black woman to head a college science department. 1889: American astronomer Antonia Maury discovered the second spectroscopic binary, Beta Aurigae, and calculated its orbital period. 1889: American geologist Mary Emilie Holmes became the first female Fellow of the Geological Society of America.
=== Shelf life === The shelf life of canned evaporated milk varies according to both its added content and its proportion of fat. For the regular unsweetened product, a shelf life of 15 months may be expected before any noticeable destabilization occurs.
=== Production quantities === World production was approximately 1,100 kt in 2017, with the bulk being produced in China (930 kt) and Russia (60 kt). The United States was in the 20th century the major world supplier of this metal, supplying 45% of world production even as recently as 1995. Since the Chinese mastery of the Pidgeon process the US market share is at 7%, with a single US producer left as of 2013: US Magnesium, a Renco Group company located on the shores of the Great Salt Lake. In September 2021, China took steps to reduce production of magnesium as a result of a government initiative to reduce energy availability for manufacturing industries, leading to a significant price increase.
== Bibliography == Michel Demopoulos, directeur de publication, Le Cinéma grec [Greek Cinema], Paris, Centre Georges Pompidou, collection «cinéma/pluriel,» 1995, 263 pages, ISBN 2858508135. (in French) Vrasidas Karalis, A History of Greek Cinema, New York, New York and London, Continuum International Publishing Group, 2012, 344 pages, ISBN 978-1-4411-9447-3. Sylvie Rollet, directeur de publication (préface: Theo Angelopoulos), Théorème 9: Théo Angelopoulos au fil du temps [Theo Angelopoulos over the Course of Time], Paris, Presses Sorbonne Nouvelle, 2007, 189 pages, ISBN 978-2-87854-372-8. (in French) Stéphane Sawas, «Grèce (1967–1974) – Les écrans grecs sous la dictature des colonels: la grande rupture,» [Greece (1967–1974) – Greek Screens Under the Dictatorship of the Colonels: The Great Break] dans Raphaël Muller et Thomas Wieder, directeurs de publication, Cinéma et régimes autoritaires au xxe siècle: Écrans sous influence [Cinema and Authoritarian Regimes in the Twentieth Century: Screens Under Influence], Paris, Éditions École Normale Supérieure rue d'Ulm et Presses Universitaires de France, collection «Les rencontres de Normale Sup',» 2008, 285 pages, ISBN 978-2-13-055749-4.
Sources: en.wikipedia.org
=== Pharmacokinetics === Gepotidacin is rapidly absorbed orally, reaching peak plasma concentrations (tmax) after approximately 2.0 hours. In adults with uncomplicated urinary tract infections (uUTI) and normal renal function, the mean steady-state maximum concentration (Cmax) is 4.2 mcg/mL, and the area under the concentration-time curve over 12 hours AUC(0-12) is 22.8 mcg*hour/mL following a 1500 mg dose every 12 hours. Systemic exposure (Cmax and AUC) increases proportionally with dose. Accumulation of approximately 40% occurs and achieves a steady state by day 3. The absolute bioavailability is about 45%, and standard and moderate fat meals did not significantly affect its absorption. Gepotidacin's pharmacokinetics were found to be generally consistent across different ages, sexes, races, and body weights during modeling and simulation. Gepotidacin has a mean steady-state volume of distribution (Vss) of 172.9 liters and is 25-41% bound to plasma proteins. It has a terminal elimination half-life of approximately 9.3 hours and a total clearance of 33.4 L/hour. The primary metabolic pathway involves CYP3A4, with a minor metabolite (M4, ~11% of circulating drug). The co-administration of other drugs can influence gepotidacin levels. Strong inhibitors of CYP3A4 can increase gepotidacin exposure, whereas strong inducers of CYP3A4 can decrease it. Additionally, gepotidacin, at high concentrations, has shown the potential to increase the exposure of certain other drugs, including digoxin and midazolam.
== Research == Myopathies have been modeled with cell culture systems of muscle from healthy or diseased tissue biopsies. Another source of skeletal muscle and progenitors is provided by the directed differentiation of pluripotent stem cells. Research on skeletal muscle properties uses many techniques. Electrical muscle stimulation is used to determine force and contraction speed at different frequencies related to fiber-type composition and mix within an individual muscle group. In vitro muscle testing is used for more complete characterization of muscle properties. The electrical activity associated with muscle contraction is measured via electromyography (EMG). Skeletal muscle has two physiological responses: relaxation and contraction. The mechanisms for which these responses occur generate electrical activity measured by EMG. Specifically, EMG can measure the action potential of a skeletal muscle, which occurs from the hyperpolarization of the motor axons from nerve impulses sent to the muscle. EMG is used in research for determining if the skeletal muscle of interest is being activated, the amount of force generated, and an indicator of muscle fatigue. The two types of EMG are intra-muscular EMG and the most common, surface EMG. The EMG signals are much greater when a skeletal muscle is contracting versus relaxing. However, for smaller and deeper skeletal muscles the EMG signals are reduced and therefore are viewed as a less valued technique for measuring the activation.
Apart from traditional uranium charges, combinations of uranium with americium and thorium have been tried, as well as a mixed plutonium-neptunium charge, but they were less successful in terms of yield and was attributed to stronger losses of heavy isotopes due to enhanced fission rates in heavy-element charges. Product isolation was problematic as the explosions were spreading debris through melting and vaporizing the surrounding rocks at depths of 300–600 meters. Drilling to such depths to extract the products was both slow and inefficient in terms of collected volumes. Of the nine underground tests between 1962 and 1969, the last one was the most powerful and had the highest yield of transuranics. Milligrams of einsteinium that would normally take a year of irradiation in a high-power reactor, were produced within a microsecond. However, the major practical problem of the entire proposal was collecting the radioactive debris dispersed by the powerful blast. Aircraft filters adsorbed only ~4×10−14 of the total amount, and collection of tons of corals at Enewetak Atoll increased this fraction by only two orders of magnitude. Extraction of about 500 kilograms of underground rocks 60 days after the Hutch explosion recovered only ~1×10−7 of the total charge. The amount of transuranic elements in this 500 kg batch was only 30 times higher than in a 0.4-kg rock picked up 7 days after the test which showed the highly non-linear dependence of the transuranics yield on the amount of retrieved radioactive rock.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽，它难以通过胃肠道吸收，通常需要注射给药。口服会因消化酶降解而失去活性，因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.